The University of California San Diego Health System, a leader in chronic thromboembolic pulmonary hypertension (CTEPH) research and patient care, has just received a generous grant to fund the recent launch of the country’s first CTEPH registry. The $7.6 million grant comes from pharmaceutical giant Bayer HealthCare in time for the November Pulmonary…

Vanderbilt Heart & Vascular Institute (VHVI) is offering a novel and specialized surgical approach for treating patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension (PH) that can cause breathing difficulties, acute pulmonary embolism, or blood clots in the lung. Even though the condition…

Bayer HealthCare recently launched a contest with the goal of raising awareness about pulmonary hypertension (PH) and gathering support for PH patients and their families. Of particular focus in this contest is a type of PH called CTEPH, or chronic thromboembolic pulmonary hypertension. Breathless Moments…

November 18th has been officially named chronic thromboembolic pulmonary hypertension (CTEPH) Awareness Day. This will be the first ever awareness day dedicated specifically to CTEPH. Chronic thromboembolic pulmonary hypertension is caused by chronic blood clots in the lungs that cause pressure in the pulmonary arteries and the right side…

Patients with chronic thromboembolic pulmonary hypertension (CTEPH) who respond differently to treatment with pulmonary endarterectomy (PEA) may have differences in microvascular structure. When a team of researchers from Paris-South University and Centre Chirugical Marie Lannelongue investigated CTEPH pathogenesis in humans, they applied their findings related to microvasculature changes…

New insights into the molecular mechanisms of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH) generally lead to new avenues of research for treatments that may work better than existing treatments or open the doors for previously untreatable patients. Work from Medical University Vienna in Austria,…

Findings collected during more than two years confirming the safety and efficacy of Bayer’s Adempas® (riociguat) in treating either inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), and patients with pulmonary arterial hypertension (PAH) were recently presented at the European Respiratory Society (ERS) Congress. Riociguat is the first member of…

A team of researchers has published their results assessing left atrial volume in chronic thromboembolic pulmonary hypertension (CTEPH) patients before and after pulmonary thromboendarterectomy (PTE), a surgical procedure that removes organized, clotted blood from the pulmonary arteries. When the body cannot reabsorb a pulmonary embolism (PE), clots…

Some of the most difficult-to-treat patients with pulmonary hypertension are those with chronic thromboembolic pulmonary hypertension (CTEPH). These patients are in the most severe category of pulmonary hypertension: World Health Organization (WHO) Group 4. CTEPH patients have curative potential if they have no resectable lesions or contraindications…

Endothelin-receptor antagonists (ERAs), recently discussed on Pulmonary Hypertension News as being effective for treating pulmonary hypertension, have been a standard part of clinician’s portfolios along with phosphodiesterase type 5 inhibitors and calcium channel blockers. The common definition for “treating pulmonary…

Early detection of chronic thromboembolic pulmonary hypertension (CTEPH) is vital to addressing and potentially preventing the most common cause of severe pulmonary hypertension. A number of clinical diagnostic parameters have been studied and effectively practiced, but detection can extend beyond the doctor’s office. A study…

Chronic thromboembolic pulmonary hypertension (CTEPH), a disease caused by unresolved pulmonary blood clots, is a major contributor to pulmonary hypertension. Previous reports have identified that…